Long-term Proton Pump Inhibitor Therapy And Risk Of Hip Fracture.
Yu-Xiao Yang, J. Lewis, S. Epstein, D. Metz
Published 2006 · Medicine
Download PDFAnalyze on Scholarcy
CONTEXT Proton pump inhibitors (PPIs) may interfere with calcium absorption through induction of hypochlorhydria but they also may reduce bone resorption through inhibition of osteoclastic vacuolar proton pumps. OBJECTIVE To determine the association between PPI therapy and risk of hip fracture. DESIGN, SETTING, AND PATIENTS A nested case-control study was conducted using the General Practice Research Database (1987-2003), which contains information on patients in the United Kingdom. The study cohort consisted of users of PPI therapy and nonusers of acid suppression drugs who were older than 50 years. Cases included all patients with an incident hip fracture. Controls were selected using incidence density sampling, matched for sex, index date, year of birth, and both calendar period and duration of up-to-standard follow-up before the index date. For comparison purposes, a similar nested case-control analysis for histamine 2 receptor antagonists was performed. MAIN OUTCOME MEASURE The risk of hip fractures associated with PPI use. RESULTS There were 13,556 hip fracture cases and 135,386 controls. The adjusted odds ratio (AOR) for hip fracture associated with more than 1 year of PPI therapy was 1.44 (95% confidence interval [CI], 1.30-1.59). The risk of hip fracture was significantly increased among patients prescribed long-term high-dose PPIs (AOR, 2.65; 95% CI, 1.80-3.90; P<.001). The strength of the association increased with increasing duration of PPI therapy (AOR for 1 year, 1.22 [95% CI, 1.15-1.30]; 2 years, 1.41 [95% CI, 1.28-1.56]; 3 years, 1.54 [95% CI, 1.37-1.73]; and 4 years, 1.59 [95% CI, 1.39-1.80]; P<.001 for all comparisons). CONCLUSION Long-term PPI therapy, particularly at high doses, is associated with an increased risk of hip fracture.
This paper references
Epidemiology of hip fractures.
R. Cumming (1997)
Hypochlorhydria from short-term omeprazole treatment does not inhibit intestinal absorption of calcium, phosphorus, magnesium or zinc from food in humans.
C. Serfaty-Lacrosniere (1995)
A model of lifetime osteoporosis impact.
E. Chrischilles (1991)
Effect of L-lactic acid on the absorption of calcium in gastrectomized rats.
O. Chonan (1998)
Modularity of osteoclast behaviour and “mode-specific” inhibition of osteoclast function
M. Zaidi (1990)
The General Practice Research Database: quality of morbidity data.
J. Hollowell (1997)
Selective inhibition of osteoclast vacuolar H(+)-ATPase.
C. Farina (2002)
Incidence of fractures in a geographically defined population.
L. Donaldson (1990)
The Read clinical classification.
J. Chisholm (1990)
Omeprazole, a specific inhibitor of H+−K+-ATPase, inhibits bone resorptionin vitro
J. Tuukkanen (2007)
The use of a large pharmacoepidemiological database to study exposure to oral corticosteroids and risk of fractures: validation of study population and results.
T. van Staa (2000)
Use of Statins and Risk of Fractures
T. V. Staa (2001)
B. Dunn (1997)
Proton Pump Inhibitors, Histamine H2 Receptor Antagonists, and Other Antacid Medications and the Risk of Fracture
P. Vestergaard (2006)
N Engl J Med
Chemistry of covalent inhibition of the gastric (H+, K+)-ATPase by proton pump inhibitors.
J. Shin (2004)
The relationship between time since registration and measured incidence rates in the General Practice Research Database.
J. Lewis (2005)
Thiazide Diuretics and the Risk for Hip Fracture
Mariette W C J Schoofs (2003)
Is there any association between myocardial infarction, gastro‐oesophageal reflux disease and acid‐suppressing drugs?
S. Johansson (2003)
Gastrointestinal absorption of calcium from milk and calcium salts.
M. Sheikh (1987)
A model of lifetime osteoporosis
EA Chrischilles (1991)
Effect of omeprazole, an inhibitor of H+, K+-ATPase, on bone resorption in humans
K. Mizunashi (2005)
Calcium and osteoporosis.
B. Nordin (1988)
An evaluation of the importance of gastric acid secretion in the absorption of dietary calcium.
G. Bo-Linn (1984)
Mortality, Disability, and Nursing Home Use for Persons with and without Hip Fracture: A Population‐Based Study
C. Leibson (2002)
H. Orimo (1991)
Am J Gastroenterol
Bj Marshall (1994)
Regulation of vitamin D and calcium metabolism after gastrectomy.
L. Nilas (1985)
Biased selection of controls for case-control analyses of cohort studies.
J. Lubin (1984)
Calcium absorption and achlorhydria.
R. Recker (1985)
Effect of L-lactic acid on calcium absorption in rats fed omeprazole.
O. Chonan (1998)
Pharmacokinetic Study of Omeprazole in Elderly Healthy Volunteers
S. Landahl (1992)
Calcium Supplement and Bone Medication Use in a US Medicare Health Maintenance Organization
B. Dawson-Hughes (2002)
The absorption of calcium carbonate.
P. Ivanovich (1967)
Who is using chronic acid-suppression therapy and why?
B. Jacobson (2000)
Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles.
A. Chan (2004)
OXMIS Problem Codes for Primary Medical Care
J. Perry (1978)
The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials.
D. Felson (1993)
Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial.
M. B. O'Connell (2005)
Risk of fractures in patients with pernicious anemia
J. Goerss (1992)
Use of Inhaled Corticosteroids and Risk of Fractures
T. P. Van Staa (2000)
This paper is referenced by
The pharmacology of esomeprazole and its role in gastric acid related diseases
C. Saccar (2009)
What's new in orthopaedic trauma.
P. Cole (2005)
Frecuencia de la prescripción de los inhibidores de bomba de protones basada en guías de práctica clínica en pacientes hospitalizados en dos hospitales docentes de Lima - Perú
Katherine Yelenia Bustamante Robles (2012)
Comparing omeprazole with fluoxetine for treatment of patients with heartburn and normal endoscopy who failed once daily proton pump inhibitors: double-blind placebo-controlled trial.
M. R. Ostovaneh (2014)
Safety of Proton Pump Inhibitors in Community-Dwelling Older Adults
Adrienne J. Lindblad (2008)
The use of calcium and vitamin D in the management of osteoporosis
J. Sunyecz (2008)
Overutilization of Proton Pump Inhibitors: A Review of Cost-Effectiveness and Risk in PPI
J. Heidelbaugh (2009)
Substitution of dalteparin with enoxaparin-a cautionary note.
Conor J. Magee (2010)
Kapitel 4 – Krankheitsbilder
Jan Hildebrandt (2012)
Nizatidine Improves Clinical Symptoms and Gastric Emptying in Patients with Functional Dyspepsia Accompanied by Impaired Gastric Emptying
S. Futagami (2012)
CHAPTER 8 – Osteoporosis
M T Mcdermott (2013)
Inhibiteurs de la pompe à protons pour les nourrissons irritables
Christine H. Smith (2013)
Gastroprotezione con inibitori di pompa protonica in ospedale: oltre all’(ab)uso, anche eventi avversi?
Paolo Montanari (2010)
Rational use of nonsteroidal anti-inflammatory drugs and proton pump inhibitors in combination for rheumatic diseases
Klaus-Miehlke Klinik (2010)
Association of Proton Pump Inhibitor Use with Recurrent Falls and Risk of Fractures in Older Women: A Study of Medication Use in Older Fallers.
Heinrich Wolfgang Thaler (2016)
Impact de l'hospitalisation sur la polymédication des personnes âgées et évaluation à six mois après la sortie auprès des médecins généralistes : cas particulier des inhibiteurs de la pompe à protons
Julie Nava Maire (2015)
Proton Pump Inhibitors and Risk of Rhabdomyolysis
Scott Joseph Duncan (2016)
A Comparison of Histamine Receptor Antagonists Versus Proton Pump Inhibitor Gastrointestinal Ulcer Prophylaxis in Kidney Transplant Recipients
Ginger E Rouse (2017)
Complex Relationship Between Proton Pump Inhibitor Use and Bone Health
Ting Zhu (2017)
Micromotor-enabled active drug delivery for in vivo treatment of stomach infection
Berta Esteban-Fernández de Ávila (2017)
Over-prescription of acid-suppressing medications in infants: how it came about, why it's wrong, and what to do about it.
E. Hassall (2012)
The relative efficacies of gastroprotective strategies in chronic users of nonsteroidal anti-inflammatory drugs.
L. Targownik (2008)
Clinical epidemiological studies of drug safety and disease risk factors using large primary care databases
Yana Vinogradova (2017)
Proton pump inhibitor use and risk of dementia
Min Li (2019)
ACVIM consensus statement: Support for rational administration of gastrointestinal protectants to dogs and cats
S. Marks (2018)
Adverse outcomes of long-term use of proton pump inhibitors: a systematic review and meta-analysis
M. M. Islam (2018)
Osteoporosis in Depression: Which Patients Are at Risk? Psychotropics Increase Fracture Risk; Depression Compounds Poor Bone Health
Charles Hébert (2010)
Helicobacter pylori: A Possible Risk Factor for Bone Health
Y. H. Chung (2015)
The many manifestations of gastroesophageal reflux disease: presentation, evaluation, and treatment.
J. Richter (2007)
Long-term proton pump inhibitor use and effect on risk of fractures
H. Messer (2018)
Strategies for peptic ulcer healing after 1 week proton pump inhibitor-based triple Helicobacter pylori eradication therapy in Japanese patients: differences of gastric ulcers and duodenal ulcers
T. Takeuchi (2012)
Patient and physician predictors of inappropriate acid-suppressive therapy (AST) use in hospitalized patients.
J. Nachnani (2009)See more